An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
1,000actual
Sites
38
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-07 | actual | When the study began enrolling |
| Primary completion | 2026-05-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-25 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with a dose change
measured 12 Months
Number of participants with Upadacitinib drug compliance
measured 12 Months
Number of participants with interruption or permanent discontinuation
measured 12 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed